Australia markets close in 2 hours 46 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.37+0.95 (+2.19%)
At close: 04:00PM EDT
44.44 +0.07 (+0.16%)
After hours: 07:49PM EDT

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
https://www.sanofi.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees95,442

Key executives

NameTitlePayExercisedYear born
Mr. Paul HudsonCEO & Director5.82MN/A1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFON/AN/A1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingN/AN/AN/A
Mr. Bruno MénardChief Information officerN/AN/AN/A
Dr. Josephine FubaraChief Science Officer of Consumer Health CareN/AN/AN/A
Eva Schaefer-JansenHead of Investor RelationsN/AN/AN/A
Mr. Dante BeccariaGlobal Compliance Officer & VPN/AN/AN/A
Mr. Roy PapatheodorouExec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. IntegrityN/AN/A1978
Mr. Josep CatllaHead of CommunicationsN/AN/AN/A
Mr. Pierre ChancelSr. VP of Global Diabetes and Sr. VP of Global MarketingN/AN/A1957
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Corporate governance

Sanofi’s ISS governance QualityScore as of 31 July 2022 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.